Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis

被引:19
|
作者
Berti, Alvise [1 ,2 ]
Volcheck, Gerald W. [3 ]
Cornec, Divi [2 ,4 ]
Smyth, Robert J. [5 ]
Specks, Ulrich [2 ]
Keogh, Karina A. [2 ]
机构
[1] Milan & Santa Chiara Hosp, Immunol Rheumatol Allergy & Rare Dis Dept, San Raffaele Sci Inst, Trento, Italy
[2] Mayo Clin, Div Pulm & Crit Care Med, Coll Med & Sci, Rochester, MN 55905 USA
[3] Mayo Clin, Div Allerg Dis, Dept Med, Rochester, MN 55905 USA
[4] Univ Bretagne Occidentale, CHU Brest, INSERM, UMR1227,Lymphocytes & Autoimmunite B, Brest, France
[5] Royal Coll Surgeons Ireland, Dublin 2, Dublin, Ireland
关键词
Severe asthma; Asthma; Atopy; Specific IgE; Skin test; Eosinophilic granulomatosis with polyangiitis; EGPA; Churg-strauss; ANCA-Associated vasculitis; Survival; CHURG-STRAUSS-SYNDROME; TERM-FOLLOW-UP; INNER-CITY CHILDREN; SYSTEMIC VASCULITIS; NOMENCLATURE; OMALIZUMAB; PHENOTYPES; ALLERGY;
D O I
10.1016/j.rmed.2018.07.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although asthma, rhinitis/rhinosinusitis and peripheral eosinophilia are present in virtually all patients with eosinophilic granulomatosis with polyangiitis (EGPA), the role of atopy in these patients is not well defined. Objective: To clarify the role of atopy in patients affected with EGPA. Methods: Clinical, laboratory and standard spirometry data have been abstracted from medical records. Only patients who underwent skin and/or specific IgE testing for common aeroallergens before the vasculitic phase were included. Results: Overall, 33.5% (63) of our patients underwent skin and/or specific IgE testing to aeroallergens. Atopy related to aeroallergens was confirmed in 22.3% (two-third of those tested), and was associated with more severe/uncontrolled asthma (p < 0.001), including a greater use of oral glucocorticoids for respiratory manifestations the year before the diagnosis of EGPA (p = 0.013). Atopic patients with EGPA had higher total serum IgE levels and less renal disease at EGPA diagnosis compared to non-atopic patients (p < 0.05). Among atopic patients, the majority had multiple sensitizations (76%); dust mite and grass pollen were the most common respiratory allergens identified. The number of allergens did not correlate with peripheral eosinophilia, total serum IgE, ESR, or measures of airway obstruction (p > 0.05 in all cases). The presence of atopy increased the risk of severe/uncontrolled asthma, but not the risk of severe vasculitis (Five Factor Score >= 1). Atopic patients had a better overall survival (p = 0.027). Conclusion: In EGPA, atopy is associated with better prognosis and more severe/uncontrolled asthma manifestations in the year before the development of vasculitis, but not with more severe vasculitis at presentation.
引用
收藏
页码:66 / 72
页数:7
相关论文
共 50 条
  • [21] Omalizumab treatment in patient with severe Asthma and Eosinophilic Granulomatosis with Polyangiitis. A case report
    Graziani, A.
    Quercia, O.
    Girelli, F.
    Martelli, A.
    Cappa, F. Mirici
    Stefanini, G. F.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 46 (06) : 226 - 228
  • [22] OMALIZUMAB TREATMENT IN TEEN PATIENT WITH SEVERE ASTHMA AND EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: CASE REPORT
    Garcia Fajardo, D.
    Perez, H.
    Del Rio Navarro, B.
    Saucedo Ramirez, O.
    Del Rio-Chivardi, J.
    Rodriguez, E.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 117 (05) : S70 - S70
  • [23] Transient severe precapillary pulmonary hypertension caused by eosinophilic granulomatosis with polyangiitis in a patient with asthma
    Jermakow, Mateusz
    Danielewicz, Klaudia
    Dudzinska, Klaudia
    Bienias, Piotr
    Roik, Marek
    Pruszczyk, Piotr
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2024, 134 (7-8):
  • [24] Severe Asthma Where Eosinophilic Granulomatosis with Polyangiitis Became Apparent after the Discontinuation of Dupilumab
    Ikeda, Miki
    Ohshima, Nobuharu
    Kawashima, Masahiro
    Shiina, Meiko
    Kitani, Masashi
    Suzukawa, Maho
    INTERNAL MEDICINE, 2022, 61 (05) : 755 - 759
  • [25] Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis
    Padoan, Roberto
    Bianchi, Fulvia Chieco
    Marchi, Maria Rita
    Cazzador, Diego
    Felicetti, Mara
    Emanuelli, Enzo
    Vianello, Andrea
    Nicolai, Piero
    Doria, Andrea
    Schiavon, Franco
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (09): : 3225 - +
  • [26] Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab
    Moura, Marta Casal
    Berti, Alvise
    Keogh, Karina A.
    Volcheck, Gerald W.
    Specks, Ulrich
    Baqir, Misbah
    CLINICAL RHEUMATOLOGY, 2020, 39 (05) : 1581 - 1590
  • [27] Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis
    Moiseev, Sergey
    Zagvozdkina, Eugenia
    Kazarina, Viktoria
    Bulanov, Nikolai
    Novikov, Pavel
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 144 (02) : 621 - 621
  • [28] ASTHMA CONTROL IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATED WITH RITUXIMAB
    Moura, Marta Casal
    Berti, Alvise
    Keogh, Karina
    Volcheck, Gerald
    Specks, Ulrich
    Baqir, Misbah
    RHEUMATOLOGY, 2019, 58 : 128 - 129
  • [29] Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab
    Marta Casal Moura
    Alvise Berti
    Karina A. Keogh
    Gerald W. Volcheck
    Ulrich Specks
    Misbah Baqir
    Clinical Rheumatology, 2020, 39 : 1581 - 1590
  • [30] Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma
    Pagnoux, C.
    Nair, P.
    Xi, Y.
    Khalidi, N. A.
    Carette, S.
    Cuthbertson, D.
    Grayson, P. C.
    Koening, C. L.
    Langford, C. A.
    McAlear, C. A.
    Moreland, L. W.
    Monach, P. A.
    Seo, P.
    Specks, U.
    Sreih, A. G.
    Ytterberg, S. R.
    Tyrrell, P. N.
    Merkel, P. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (02) : S40 - S44